BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25373854)

  • 21. Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: A Retrospective, Single-Center Study of 55 Patients.
    Bhandari RP; Stanford JD; Packianathan S; Duggar WN; Kanakamedala MR; Zhang X; Giri SP; Kumar PP; Harrell LM; Mangana SH; Yang C; Vijayakumar S
    Oncology; 2016; 91(4):194-204. PubMed ID: 27427761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel.
    Barriger RB; Fakiris AJ; Hanna N; Yu M; Mantravadi P; McGarry RC
    Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1381-6. PubMed ID: 20231061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and Dosimetric Factors Predicting Grade ≥2 Radiation Pneumonitis After Postoperative Radiotherapy for Patients With Non-Small Cell Lung Carcinoma.
    Boonyawan K; Gomez DR; Komaki R; Xu Y; Nantavithya C; Allen PK; Mohan R; Liao Z
    Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):919-926. PubMed ID: 29976504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors.
    Parker SM; Siochi RA; Wen S; Mattes MD
    Pract Radiat Oncol; 2019 Jan; 9(1):e90-e97. PubMed ID: 30267899
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival in Patients Treated With Lung Stereotactic Body Radiation Therapy (SBRT).
    Glick D; Lyen S; Kandel S; Shapera S; Le LW; Lindsay P; Wong O; Bezjak A; Brade A; Cho BCJ; Hope A; Sun A; Giuliani M
    Clin Lung Cancer; 2018 Mar; 19(2):e219-e226. PubMed ID: 29066051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stereotactic body radiation therapy for post-pulmonary lobectomy isolated lung metastasis of thoracic tumor: survival and side effects.
    Xiong W; Xu Q; Xu Y; Sun C; Li N; Zhou L; Liu Y; Zhou X; Wang Y; Wang J; Bai S; Lu Y; Gong Y
    BMC Cancer; 2014 Sep; 14():719. PubMed ID: 25260301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stereotactic body radiotherapy for second primary lung cancer and intra-parenchymal lung metastasis in patients previously treated with surgery: evaluation of indications and predictors of decreased respiratory function.
    Ishihara T; Yamada K; Harada A; Yukiue H; Tanahashi M; Niwa H; Matsui T; Yokomura K; Ejima Y; Sasaki R
    Acta Oncol; 2018 Sep; 57(9):1232-1239. PubMed ID: 29722594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Temporal and spatial dose distribution of radiation pneumonitis after concurrent radiochemotherapy in stage III non-small cell cancer patients.
    Alharbi M; Janssen S; Golpon H; Bremer M; Henkenberens C
    Radiat Oncol; 2017 Nov; 12(1):165. PubMed ID: 29096667
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Radiation pneumonitis after stereotactic body radiation therapy for early stage non-small cell lung cancer].
    Chen L; Zhao Y; Xu F
    Zhongguo Fei Ai Za Zhi; 2014 Apr; 17(4):351-6. PubMed ID: 24758912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin-converting enzyme inhibitors decrease the risk of radiation pneumonitis after stereotactic body radiation therapy.
    Harder EM; Park HS; Nath SK; Mancini BR; Decker RH
    Pract Radiat Oncol; 2015; 5(6):e643-9. PubMed ID: 26412341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiomic prediction of radiation pneumonitis on pretreatment planning computed tomography images prior to lung cancer stereotactic body radiation therapy.
    Hirose TA; Arimura H; Ninomiya K; Yoshitake T; Fukunaga JI; Shioyama Y
    Sci Rep; 2020 Nov; 10(1):20424. PubMed ID: 33235324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR).
    Chaudhuri AA; Binkley MS; Rigdon J; Carter JN; Aggarwal S; Dudley SA; Qian Y; Kumar KA; Hara WY; Gensheimer M; Nair VS; Maxim PG; Shultz DB; Bush K; Trakul N; Le QT; Diehn M; Loo BW; Guo HH
    Radiother Oncol; 2016 Jun; 119(3):454-60. PubMed ID: 27267049
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Study of the predictors for radiation pneumonitis in patient with non-small cell lung cancer received radiotherapy after pneumonectomy.
    Yu JH; Wang CL; Liu Y; Wang JM; Lv CX; Liu J; Zhang Q; Fu XL; Cai XW
    Cancer Radiother; 2021 Jun; 25(4):323-329. PubMed ID: 33446419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors for symptomatic radiation pneumonitis after stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer.
    Liu Y; Wang W; Shiue K; Yao H; Cerra-Franco A; Shapiro RH; Huang KC; Vile D; Langer M; Watson G; Bartlett G; Ai H; Sheski F; Jin JY; Zellars R; Fu P; Lautenschlaeger T; Kong FS
    Radiother Oncol; 2021 Mar; 156():231-238. PubMed ID: 33096168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Radiotherapy of Lung Tumours in Idiopathic Pulmonary Fibrosis].
    Kolek V; Vašáková M; Šterclová M; Cwiertka K; Vrána D; Kudláček A; Skřičková J; Pešek M; Petera J
    Klin Onkol; 2017; 30(4):303-306. PubMed ID: 28832178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive parameters of symptomatic radiation pneumonitis following stereotactic or hypofractionated radiotherapy delivered using volumetric modulated arcs.
    Bongers EM; Botticella A; Palma DA; Haasbeek CJ; Warner A; Verbakel WF; Slotman B; Ricardi U; Senan S
    Radiother Oncol; 2013 Oct; 109(1):95-9. PubMed ID: 24183862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stereotactic body radiotherapy for operable early-stage non-small cell lung cancer.
    Eriguchi T; Takeda A; Sanuki N; Tsurugai Y; Aoki Y; Oku Y; Hara Y; Akiba T; Shigematsu N
    Lung Cancer; 2017 Jul; 109():62-67. PubMed ID: 28577952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pilot Study of the Safety and Efficacy of Dose Escalation in Stereotactic Body Radiotherapy for Peripheral Lung Tumors.
    Mitsuyoshi T; Matsuo Y; Shintani T; Iizuka Y; Ueki N; Nakamura M; Mizowaki T
    Clin Lung Cancer; 2018 May; 19(3):e287-e296. PubMed ID: 29277565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modeling radiation pneumonitis of pulmonary stereotactic body radiotherapy: The impact of a local dose-effect relationship for lung perfusion loss.
    Selvaraj J; Lebesque J; Hope A; Guckenberger M; Werner-Wasik M; Peulen H; Giuliani M; Mantel F; Belderbos J; Grills I; Sonke JJ
    Radiother Oncol; 2019 Mar; 132():142-147. PubMed ID: 30825963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiation-induced lung toxicity predictors: Retrospective analysis of 90 patients treated with stereotactic body radiation therapy for stage I non-small-cell lung carcinoma.
    Menoux I; Antoni D; Mazzara C; Labani A; Charloux A; Quoix E; Falcoz PE; Truntzer P; Noël G
    Cancer Radiother; 2020 Apr; 24(2):120-127. PubMed ID: 32173269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.